Buy Sermorelin Peptide 10 mg Online | GHRH(1-29) | ≥99% Purity | CoA Included | SourceTides

Buy Sermorelin Peptide 10 mg Online from SourceTides — the research-grade synthetic GHRH(1-29) analog (CAS 86168-78-7; also known as GRF(1-29) amide) supplied at ≥99% HPLC-verified purity with a full lot-specific Certificate of Analysis. Sermorelin is the shortest fully active fragment of endogenous growth hormone-releasing hormone (GHRH), retaining complete biological potency at the pituitary GHRH receptor and offering a uniquely physiological model for studying the hypothalamic-pituitary-somatotropic axis. Every SourceTides vial is lyophilised under ISO-grade conditions, independently endotoxin-tested (LAL <1 EU/mg), and dispatched on validated dry-ice cold chain. For in-vitro laboratory and preclinical research use only — not for human consumption.

Sermorelin 10 mg Technical Specifications

What Is Sermorelin Peptide?

Sermorelin (INN; brand name Geref, discontinued) is a synthetic 29-amino-acid peptide representing the biologically active N-terminal fragment of endogenous human growth hormone-releasing hormone (GHRH). Formally designated GHRH(1-29) or GRF(1-29) amide, Sermorelin is the shortest fully functional fragment of the native 44-amino-acid GHRH molecule — retaining complete agonist activity at the pituitary GHRH receptor despite comprising only the first 29 residues of the parent hormone. This structural economy makes Sermorelin one of the most precisely characterised and historically significant research peptides in the growth hormone biology literature.

Sermorelin was developed during the late 1970s and 1980s as part of the broader scientific effort to identify the minimal active sequence of GHRH following the landmark 1982 isolation of native GHRH from human pancreatic tumours. It was ultimately approved by the US FDA in 1997 under the brand name Geref (Serono Laboratories) for two indications: (1) as a diagnostic agent to assess pituitary growth hormone reserve (GH secretory capacity), and (2) as a treatment for idiopathic growth hormone deficiency in children. Geref was subsequently discontinued for commercial reasons, but the underlying compound remains the gold-standard reference GHRH agonist for preclinical research and is available through research peptide suppliers.

The scientific value of Sermorelin for researchers lies primarily in its preservation of the body’s natural hypothalamic-pituitary feedback architecture. Unlike exogenous recombinant human GH (rhGH), which delivers preformed hormone directly and suppresses hypothalamic GHRH signalling, Sermorelin acts upstream — stimulating pituitary somatotrophs to synthesise and release their own endogenous GH in a physiologically pulsatile pattern. This approach preserves somatostatin-mediated negative feedback, prevents supraphysiological GH levels, and models the natural somatotropic axis with considerably higher biological fidelity than direct GH replacement. For researchers designing experiments to study the hypothalamic-pituitary-GH-IGF-1 axis, ageing-related GH decline, body composition regulation, or neuroprotection, Sermorelin 10 mg from SourceTides is the physiologically authentic reference compound.

Mechanism of Action: How Sermorelin Stimulates Growth Hormone Release

Sermorelin’s mechanism of action operates through the hypothalamic-pituitary-growth hormone (HPGH) axis, engaging a well-characterised G-protein-coupled receptor signalling cascade that culminates in pulsatile endogenous GH secretion. Understanding these molecular steps is essential for designing valid in-vitro and in-vivo research protocols using Sermorelin as a GHRH agonist tool compound.

1. GHRH Receptor Binding and Gαs-cAMP-PKA Signalling Cascade

Sermorelin binds with high affinity and selectivity to the GHRH receptor (GHRH-R), a seven-transmembrane Gαs-protein-coupled receptor expressed predominantly on anterior pituitary somatotroph cells. Upon binding, Sermorelin induces a conformational change that activates the coupled Gαs subunit, which in turn stimulates adenylate cyclase to catalyse the conversion of ATP to cyclic AMP (cAMP). The resulting intracellular cAMP surge activates cAMP-dependent protein kinase A (PKA), which phosphorylates multiple downstream effectors including the transcription factor CREB (cAMP response element-binding protein), leading to: (1) rapid exocytosis of pre-formed GH secretory granules from somatotrophs (within minutes); and (2) longer-term upregulation of GH gene transcription, increasing the somatotroph’s GH synthetic capacity over repeated exposures. In anterior pituitary cell culture models, Sermorelin produces a dose-dependent increase in GH secretion that is concentration-dependent, receptor-mediated, and reversible — characteristics that make it an ideal positive control and tool compound for pituitary cell biology studies. The cAMP signal also increases intracellular Ca²⁺ influx via voltage-gated calcium channels, contributing to the exocytotic GH release signal.

2. Physiological Pulsatile GH Secretion and the Somatostat Feedback Axis

A defining and research-relevant feature of Sermorelin’s mechanism is its preservation of the somatostatin-mediated negative feedback loop — a property categorically absent from exogenous rhGH administration. After Sermorelin stimulates a GH pulse, rising GH and IGF-1 levels act on the hypothalamus to increase somatostatin (SRIF) release, which inhibits further GHRH and GH secretion. This intact feedback mechanism prevents GH levels from rising into supraphysiological ranges and maintains the pulsatile, circadian-modulated pattern of GH release that characterises normal endocrine physiology. Approximately 3 hours after a Sermorelin-stimulated GH pulse, GH levels return to baseline as somatostatin suppression is resolved, permitting the subsequent pulse. This mechanism fundamentally distinguishes Sermorelin-based research models from rhGH-based models: in Sermorelin experiments, the pituitary’s own GH stores and secretory capacity are the rate-limiting factors, providing a biologically realistic ceiling. For neuroendocrinology researchers studying the HPGH axis, this pulsatile secretory pattern enables experiments that model physiologically relevant GH dynamics rather than pharmacological GH exposure.

3. Downstream IGF-1 Axis and Tissue-Level Anabolic Effects

The primary downstream mediator of Sermorelin’s biological effects — operating one step beyond the GH pulse it generates — is insulin-like growth factor-1 (IGF-1), which is synthesised and secreted principally by hepatocytes in response to GH receptor activation. GH binds to GH receptors (GHR) on hepatocytes, activating the JAK2-STAT5 signalling pathway, which drives IGF-1 gene expression. Circulating IGF-1 then mediates the majority of Sermorelin’s downstream biological effects across multiple tissue types: IGF-1 binds its own receptor (IGF-1R) on muscle, bone, adipose, neural, and immune cells, activating the PI3K-AKT-mTOR pathway to stimulate protein synthesis, satellite cell proliferation (myogenesis), osteoblast activity (bone remodelling), lipolysis in adipose tissue, and neuroprotective signalling in the CNS. This GH → IGF-1 → tissue axis is the mechanistic framework underlying Sermorelin’s relevance for research into age-related somatotropic decline, sarcopenia, metabolic syndrome, and neurocognitive ageing. The GH pulse generated by Sermorelin also exerts direct, IGF-1-independent effects at peripheral tissues including hepatic glucose output, free fatty acid mobilisation from adipocytes, and direct GHR-mediated effects on immune cells.

4. GHRH Receptor Expression Beyond the Pituitary: Autocrine/Paracrine Roles

An emerging and mechanistically important dimension of Sermorelin research is the expression of GHRH-R and its splice variants (particularly SV1) in tissues outside the pituitary, including neoplastic and immune tissues. GHRH-R expression has been documented in pancreatic beta cells (where it stimulates insulin secretion), cardiomyocytes (where GHRH agonism confers cytoprotective effects following ischaemic stress), and various tumour cell lines. In glioma models specifically, GHRH-R is overexpressed in recurrent, high-grade, IDH-wildtype tumours, and Sermorelin has been identified as the compound with the highest drug sensitivity score against recurrent glioma by high-throughput drug screening (Chang et al. 2021; PMC8033379). The proposed mechanism involves Sermorelin-driven downregulation of GHRH-R expression in tumour cells (paradoxically suppressive at tumour-expression levels) and cell cycle arrest through G1/S checkpoint modulation. This autocrine/paracrine GHRH biology — distinct from the classic endocrine pituitary-GH axis — represents a frontier area of Sermorelin research with direct oncology and cardioprotection implications.

Sermorelin Research Evidence Summary

Sermorelin and the Somatotropic Axis: The Strongest Evidence Domain

Sermorelin holds an exceptionally well-evidenced position in the GHRH pharmacology literature, underpinned by decades of peer-reviewed clinical data, an FDA approval history, and continued active research across aging, oncology, and neuroscience. Its historical regulatory status — the only GHRH(1-29) fragment to receive FDA approval — provides a uniquely robust clinical dataset that researchers can use to contextualise preclinical and in-vitro experiments.

FDA Approval and the Geref Clinical Dataset

Sermorelin received FDA approval in 1997 as Geref (Serono Laboratories) for two indications: paediatric idiopathic growth hormone deficiency treatment (SC 30 µg/kg/day at bedtime) and GH reserve diagnostic testing (IV 1 µg/kg). The pivotal clinical programme demonstrated that IV Sermorelin produces a rapid, specific, and dose-dependent GH secretory response in normal subjects within 15–45 minutes of administration, with peak serum GH concentrations serving as a quantitative readout of pituitary somatotroph functional reserve. False-positive GH responses (suppressed response in non-deficient subjects) were significantly lower with Sermorelin than with alternative provocative agents (arginine, clonidine, insulin tolerance test) — a finding that established Sermorelin’s specificity advantage for pituitary function assessment. The approval also generated pharmacokinetic data that remains the definitive clinical PK reference for Sermorelin: t½ 11–12 minutes, clearance 2.4–2.8 L/min, Vd 23.7–25.8 L, peak SC Cmax at 5–20 minutes, absolute SC bioavailability ~6%. Geref was discontinued by Serono for commercial reasons unrelated to safety or efficacy — a fact that is critical to contextualise for researchers: discontinuation does not reflect any regulatory safety concern and the FDA approval history represents a robust clinical safety database.

Age-Related GH Decline Research: Restoring Somatopause

Among the most clinically significant lines of Sermorelin research is its application to somatopause — the progressive decline in GH secretory amplitude and IGF-1 levels that begins in the third decade of life and continues at approximately 14% per decade thereafter. This age-related GH decline is mechanistically driven by reduced hypothalamic GHRH signalling, increased somatostatin tone, and reduced somatotroph responsiveness. Corpas and colleagues (1992; PMID: 1379256) published a landmark study demonstrating that twice-daily SC GHRH(1-29) administration reversed the decreased GH pulse amplitude and reduced IGF-1 levels in older men, essentially restoring GH pulsatility toward profiles characteristic of younger subjects. This reversal of somatopause by GHRH agonism — rather than by direct GH replacement — is mechanistically important because it confirms that the somatotroph cell itself retains GH synthetic capacity in aging; the primary deficit lies upstream (hypothalamic GHRH decline), making GHRH-R agonists the biologically appropriate intervention model. The Vitiello et al. NIH-funded trial at the University of Washington (PMC3181657) further demonstrated that GHRH administration in older adults modulates slow-wave sleep architecture — the sleep stage during which the largest natural GH pulse occurs — connecting the somatotropic and sleep physiology research fields.

Glioma Research: An Emerging and Unexpected Research Domain

A 2021 study in the Annals of Translational Medicine by Chang et al. (PMC8033379) introduced a surprising and mechanistically novel application of Sermorelin: high-throughput in-silico drug screening of the Chinese Glioma Genome Atlas (CGGA) database, combined with validation in U87 and LN229 glioblastoma cell lines, identified Sermorelin as the compound with the lowest drug resistance score (highest predicted sensitivity) in recurrent, high-grade, IDH-wildtype, mesenchymal-subtype glioma. Mechanistically, GHRH-R is overexpressed in recurrent compared to primary glioma samples — a finding that correlates with worse prognosis and that Sermorelin appears to target therapeutically. Sermorelin treatment produced dose- and time-dependent growth inhibition in both cell lines, mediated through G1/S cell cycle arrest and negative modulation of immune checkpoints (including reduced M0 macrophage infiltration). Kaplan-Meier analysis from the CGGA database confirmed that predicted Sermorelin sensitivity correlated with improved survival independently of postoperative adjuvant treatment. This glioma research domain — entirely separate from Sermorelin’s GHRH-R pituitary mechanism — reflects the broader autocrine/paracrine biology of GHRH-R expression in tumour cells and opens a distinct cancer biology research avenue for Sermorelin.

What Research Is Sermorelin Most Relevant For?

Sermorelin Pharmacokinetics for Research Design

Sermorelin Side Effects and Safety Profile: Research Context

SourceTides Quality Control: Sermorelin Peptide 10 mg

When you buy Sermorelin Peptide 10 mg online from SourceTides, every batch undergoes a rigorous QC programme designed to meet the standards required for peer-reviewed research. Sermorelin’s 29-amino-acid sequence includes a methionine residue (Met-27) susceptible to oxidation — our QC protocols specifically assess oxidation status.

Sermorelin Regulatory Status by Jurisdiction

Sermorelin vs Related GH Axis Research Peptides

Peer-Reviewed References for Sermorelin Research

Frequently Researched Alongside Sermorelin — Related SourceTides Peptides

Researchers studying the GH axis, somatotropic ageing, and hypothalamic-pituitary endocrinology routinely pair Sermorelin with the following compounds available from SourceTides:

• Ipamorelin research peptide — GHS-R1a (ghrelin receptor) agonist; synergistic with Sermorelin for dual-axis GH stimulation (GHRH-R + GHS-R1a simultaneously); most common Sermorelin co-administration research compound
• CJC-1295 research peptide — Extended-half-life GHRH analog with DAC technology; directly comparable to Sermorelin for pulsatile vs tonic GH elevation mechanism comparison studies
• GHRP-2 research peptide — GHS-R1a agonist with cortisol and prolactin elevation; useful for selectivity comparison against Sermorelin’s purely GHRH-R-mediated, cortisol-neutral profile
• Tesamorelin research peptide — FDA-approved (HIV lipodystrophy) full-length GHRH(1-44) analog; important direct comparator for GHRH fragment activity studies (Sermorelin GHRH(1-29) vs Tesamorelin GHRH(1-44))
• MK-677 (Ibutamoren) research compound — Oral non-peptide GHS-R1a agonist; directly compared with Sermorelin in GH secretagogue mechanism studies; contrasting pharmacokinetic (oral, t½ ~24h) vs Sermorelin (injectable, t½ ~12min)
• IGF-1 LR3 research peptide — The primary downstream mediator of Sermorelin’s anabolic effects; studied alongside Sermorelin to dissect upstream (GHRH-R → GH → IGF-1) vs direct IGF-1R-mediated pathways

Frequently Asked Questions: Buy Sermorelin Peptide 10 mg Online